18 octubre 2008

Yondelis en Combinacion con Doxorubicin en STS . Resultados Fase I realizada por J&J . La Combinacion es Segura y Activa .

15 October 2008 .

Phase I combination study of trabectedin and Doxorubicin in patients with soft-tissue sarcoma.

Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsky C, Elsayed YA, Le Cesne A.
Authors' Affiliations: CONTICANET and UJOMM Hôpital Edouard Herrot, Centre Léon Bérard, Lyon, France.



RESULTS: Patients (N = 41) received a median of six cycles of treatment (range, 2-13). The maximum tolerated dose was trabectedin 1.1 mg/m(2) and doxorubicin 60 mg/m(2). Common grade 3/4 treatment-emergent adverse events were neutropenia (71%), alanine aminotransferase increase (46%), and thrombocytopenia (37%). Overall, 5 (12%) patients achieved a partial response and 34 (83%) maintained stable disease. Median progression-free survival was 9.2 months. Doxorubicin and trabectedin pharmacokinetics were not altered substantially with concomitant administration. CONCLUSION: The combination of doxorubicin 60 mg/m(2) followed by trabectedin 1.1 mg/m(2) every 21 days is safe and active in patients with soft-tissue sarcoma.